Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Buurman, E. T. Articles by MacCormack, K. Search for Related Content PubMed PubMed Citation Articles by Buurman, E. T. Articles by MacCormack, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2006, p. 385-387, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.385-387.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Different Modes of Action of Naphthyridones in Gram-Positive and Gram-Negative Bacteria

Ed T. Buurman,^1* Kenneth D. Johnson,¹ Roxanne K. Kelly,² and Kathy MacCormack²

Department of Microbiology,¹ Molecular Sciences, Infection Discovery, AstraZeneca R&D Boston, Waltham, Massachusetts 02451²

Received 25 July 2005/ Returned for modification 23 August 2005/ Accepted 25 August 2005

Top Abstract Text References

 
Naphthyridones that were recently described as a class of translation inhibitors in gram-positive bacteria mediate their mode of action via GyrA in Haemophilus influenzae and Escherichia coli. These are the first examples of compounds in which modes of action in different bacterial pathogens are mediated through widely different targets.

Top Abstract Text References

 
Naphthyridones A-72310 and A-692345 were studied previously as racemic mixtures and were described as a novel class of translation inhibitors (3, 12). Here, both sets of two enantiomers were separated, resulting in four compounds (Fig. 1). All compounds were tested in a transcription-translation assay using S30 fractions isolated from Escherichia coli and were confirmed to inhibit translation, with 50% inhibitory concentrations ranging from 7.5 to 26 µM (Table 1). Antimicrobial activities of the compounds tended to be more potent against gram-negative species than gram-positive bacteria (Table 1). Strains of Haemophilus influenzae and E. coli lacking AcrB and TolC, respectively, were used to assess efflux via systems containing these subunits (4, 11). Absence of the pump increased activity only modestly in H. influenzae (1- to 4-fold) but more dramatically in E. coli (4- to 32-fold), indicating the occurrence of net efflux of naphthyridones.

View larger version (22K): [in this window] [in a new window]

FIG. 1. Chemical structures of compounds 1 to 4.

View this table: [in this window] [in a new window]

TABLE 1. Biochemical and microbiological profiles of naphthyridonesc

All compounds were tested in a set of radiolabeled precursor assays (6) using Streptococcus pneumoniae. Leucine and valine, thymidine, uridine, N-acetylglucosamine, and acetic acid were used as precursors to measure inhibition of the synthesis of protein, DNA, RNA, cell walls, and fatty acids, respectively. All naphthyridones inhibited incorporation of leucine and valine at lower compound concentrations than they inhibited any other processes. These results confirm a previous study (3) which showed that the compounds mediated their modes of action (MOA) via inhibition of protein synthesis. As expected, the structurally similar quinolone ciprofloxacin preferentially inhibited incorporation of thymidine (Fig. 2). A similar outcome was obtained with Staphylococcus aureus (data not shown).

View larger version (27K): [in this window] [in a new window]

FIG. 2. Inhibition of precursor incorporation into macromolecules by naphthyridones differs in H. influenzae and S. pneumoniae. Inhibition of synthesis was measured for protein (leucine []), valine (), RNA (uridine [•]), and DNA (methylthymidine []) in H. influenzae (left) and S. pneumoniae (right); for clarity, precursors for incorporation into fatty acid (acetic acid) and peptidoglycan/cell wall (N-acetylglucosamine), which were inhibited to much lower extents, have been omitted. Results obtained with compound 1 (top) are typical for all four naphthyridone compounds; ciprofloxacin (bottom) served as a control for inhibition of DNA synthesis in both S. pneumoniae and H. influenzae. Results with additional control compounds (erythromycin, triclosan, carbonyl cyanide m-chlorophenylhydrazone, rifampin, and penicillin G) are not shown.

The hypothesis that protein synthesis was the target of the naphthyridones in S. pneumoniae was confirmed by the isolation and analysis of mutants of S. pneumoniae. Mutants resistant to the most potent compound, compound 3, were isolated after incubation for 24 h at a frequency of 10^–7 from blood agar plates containing compound 3 at 32 µg · ml^–1. Although all mutants were cross-resistant against other naphthyridones in the microdilution assay (Table 2), about half of them showed a spotty growth phenotype at higher naphthyridone concentrations. Based on previous data (3) all 16S rRNA genes and the gene encoding the S3 ribosomal protein were sequenced in one representative strain of each phenotype. The strain showing spotty growth had a G₁₀₄₉A mutation, corresponding to G₁₀₅₃ in E. coli, in all four copies of the 16S rRNA, whereas no mutation was found in the S3 gene. Conversely, the seemingly more stable mutant did not have any mutation in the 16S rRNA genes but contained an in-frame deletion in the gene encoding the S3 ribosomal protein, removing amino acids GYS₁₅₉. Although G₁₀₅₃ is immediately next to the main tetracycline binding site (9), the susceptibility to this antibiotic was not changed (Table 2). Interestingly, although the deletion in S3 does not seem close enough to G₁₀₅₃ (2) to comprise part of a putative naphthyridone binding site, its proximity to G₁₀₅₃ may be sufficient to influence that region of the ribosome, due to more indirect alterations of the structure. No cross-resistance to fluoroquinolones was observed (Table 2).

View this table: [in this window] [in a new window]

TABLE 2. Cross-resistance of naphthyridone-resistance mutants of S. pneumoniae, E. coli tolC, and H. influenzae acrB

Similar studies using H. influenzae and E. coli (data not shown) yielded different results. Inhibition of incorporation of radiolabeled precursors showed that, in these species, thymidine incorporation, and thus, DNA synthesis, was inhibited similarly to the way it was inhibited by quinolones (Fig. 2). The hypothesis that inhibition of DNA synthesis rather than protein synthesis was the target of the naphthyridones in these two gram-negative species was confirmed by isolation of mutants of AcrB- and TolC-negative H. influenzae and E. coli, respectively. Mutants to either compound 1 (at 16 and 32 µg · ml^–1 for H. influenzae acrB::cap [chloramphenicol resistant] and E. coli tolC::Tn10, respectively) or compound 3 (at 2 and 0.5 µg · ml^–1 for H. influenzae acrB::cap and E. coli tolC::Tn10, respectively) were isolated at frequencies of 10^–7 to 10^–8. In contrast to the naphthyridone-resistant mutant isolates obtained from S. pneumoniae, all mutants were found to be cross-resistant to fluoroquinolones, suggesting involvement of GyrA or ParC (7). One mutant of each compound-species combination was analyzed further (Table 2) and all mutants were found to contain mutations in gyrA. Three out of four had previously described mutations in the quinolone-resistance-determining region (8, 15, 16) and one novel mutation, E₁₅₃G, was found. Compounds 1 to 3 were tested in an in vitro supercoiling assay (10) and were found to inhibit E. coli GyrA-GyrB (Table 1).

Transcriptional profiles were determined for cultures of E. coli tolC::Tn10 which were treated for 30 min at compound concentrations that equaled their MICs (1). Multivariate analysis of all transcript levels (14) showed that treatment with naphthyridones altered the profile similarly to treatment with inhibitors of DNA synthesis ciprofloxacin, ofloxacin, or nalidixic acid, and the result was quite distinct from those of protein synthesis inhibitors chloramphenicol and tetracycline (data not shown). A similar result was obtained when the analysis was more focused, using the restricted gene set defined by Dandliker et al. (3). Whereas in B. subtilis elevated transcript levels of many ribosomal proteins were found upon treatment with naphthyridones (3), in E. coli a >2-fold increase of many of these genes was found with tetracycline and with chloramphenicol (32 and 27 out of 34 genes, respectively), but no increase was detected after treatment with naphthyridones (data not shown), suggesting that in E. coli, these naphthyridones do not inhibit growth via inhibition of protein synthesis.

Here, we confirm an earlier report that naphthyridones are in vitro inhibitors of translation in S. pneumoniae and E. coli, and that in gram-positive species, the antibacterial action is mediated via inhibition of this target (3). However, naphthyridones also inhibit DNA gyrase of E. coli in an in vitro supercoiling assay (Table 1). Since DNA gyrase is a well-established target of both coumarins (13) and quinolones (5), this implies that there are (at least) two possible targets via which naphthyridones can act. The data presented here show that, whereas the in situ inhibition of translation may occur in E. coli and H. influenzae, the antibacterial action is mediated via inhibition of DNA gyrase. Combining our results with those of Dandliker et al. (3) suggests that naphthyridones mediate their antibacterial MOA via inhibition of translation in gram-positive species and via inhibition of DNA supercoiling in gram-negative species. To our knowledge, this is the first example of compounds with widely different MOA in different bacterial pathogens. One implication is that in order to elucidate relationships between chemical structure, biochemical activity, and antimicrobial activity in different pathogens, the MOA in each species needs to be determined.

 
We thank Richard Alm, Paul Fleming, Tom Keating, Kevin Keenan, Valerie Laganas, Bob McLaughlin, Scott Mills, Linda Otterson, Adam Shapiro, Wei Yang, and Elaina Zverina for their contributions to this work.

 
* Corresponding author. Mailing address: AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451. Phone: (781) 839-4592. Fax: (781) 839-4800. E-mail: Ed.Buurman{at}astrazeneca.com.

Top Abstract Text References

 

1
1. Affymetrix. 2001. Genechip Escherichia coli antisense genome array. Expression analysis protocol 701119. Affymetrix, Santa Clara, Calif.
2
2. Brodersen, D. E., W. M. Clemons, Jr., A. P. Carter, B. T. Wimberley, and V. Ramakrishnan. 2002. Crystal structure of the 30S ribosomal subunit from Thermus thermophilus: structure of the proteins and their interaction with 16S RNA. J. Mol. Biol. 316:725-768.[CrossRef][Medline]
3
3. Dandliker, P. J., S. D. Pratt, A. M. Nilius, C. Black-Schaefer, X. Ruan, D. L. Towne, R. F. Clark, E. E. Englund, R. Wagner, M. Weitzberg, L. E. Chovan, R. K. Hickman, M. M. Daly, S. Kakavas, P. Zhong, Z. Cao, C. A. David, X. Xuei, C. G. Lerner, N. B. Soni, M. Bui, L. L. Shen, Y. Cai, P. J. Merta, A. Y. Saiki, and B. A. Beutel. 2003. Novel antibacterial class. Antimicrob. Agents Chemother. 47:3831-3839.[Abstract/Free Full Text]
4
4. Fralick, J. A. 1996. Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli. J. Bacteriol. 178:5803-5805.[Abstract/Free Full Text]
5
5. Gellert, M., K. Mizuuchi, M. H. O'Dea, T. Ito, and J. I. Tomizawa. 1977. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. Proc. Natl. Acad. Sci. USA 74:4772-4776.[Abstract/Free Full Text]
6
6. Hilliard, J. J., R. M. Goldschmidt, L. Licata, E. Z. Baum, and K. Bush. 1999. Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. Antimicrob. Agents Chemother. 43:1693-1697.[Abstract/Free Full Text]
7
7. Khodursky, A. B., E. L. Zechiedrich, and N. R. Cozzarelli. 1995. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc. Natl. Acad. Sci. USA 92:11801-11805.[Abstract/Free Full Text]
8
8. Li, X., N. Mariano, J. J. Rahal, C. M. Urban, and K. Drlica. 2004. Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob. Agents Chemother. 48:3570-3572.[Abstract/Free Full Text]
9
9. Pioletti, M., F. Schlünzen, J. Harms, R. Zarivach, M. Glühmann, H. Avila, A. Bashan, H. Bartels, T. Auerbach, C. Jacobi, T. Hartsch, A. Yonah, and F. Franceschi. 2001. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 20:1829-1839.[CrossRef][Medline]
10
10. Reece, R. J., and A. Maxwell. 1989. Tryptic fragments of the Escherichia coli DNA gyrase A protein. J. Biol. Chem. 264:19648-19653.[Abstract/Free Full Text]
11
11. Sanchez, L., W. Pan, M. Vinas, and H. Nikaido. 1997. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J. Bacteriol. 179:6855-6857.[Abstract/Free Full Text]
12
12. Shen, L. L., C. Black-Schaefer, Y. Cai, P. J. Dandliker, and B. A. Beutel. 2005. Mechanism of action of novel series of naphtyridine-type ribosome inhibitors: enhancement of tRNA footprinting at the decoding site of 16S rRNA. Antimicrob. Agents Chemother. 49:1890-1897.[Abstract/Free Full Text]
13
13. Sugino, A., N. P. Higgins, P. O. Brown, C. L. Peebles, and N. R. Cozzarelli. 1978. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc. Natl. Acad. Sci. USA 75:4838-4842.[Abstract/Free Full Text]
14
14. Umetrics AB. 2002. SIMCA-P version 10.0. Umetrics AB, Umea, Sweden.
15
15. Yoshida, H., M. Bogaki, M. Nakamura, and S. Nakamura. 1990. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob. Agents Chemother. 34:1271-1272.[Abstract/Free Full Text]
16
16. Yu, X., M. Susa, C. Knabbe, R. D. Schmid, and T. T. Bachmann. 2004. Development and validation of a diagnostic DNA microarray to detect quinolone-resistant Escherichia coli among clinical isolates. J. Clin. Microbiol. 42:4083-4091.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, January 2006, p. 385-387, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.385-387.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Buurman, E. T. Articles by MacCormack, K. Search for Related Content PubMed PubMed Citation Articles by Buurman, E. T. Articles by MacCormack, K.